- Tirzepatide reduced major cardiorenal events vs dulaglutide.
- Benefits extended across cardiovascular and kidney outcomes.
- Lower rates of death, myocardial infarction, revascularization, and renal events observed.
- Gastrointestinal adverse events were more common with tirzepatide.
- Supports broader cardiometabolic benefit of dual glucagon-like peptide-1/glucose-dependent insulinotropic polypeptide therapy.
Source: JAMA Cardiology
